close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eton Pharmaceuticals, Inc. - Common Stock (NQ:ETON)

62.12 -1.31 (-2.07%)
Streaming Delayed Price Updated: 2:46 PM EDT, Aug 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eton Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Via Chartmill
News headline image
Why Eton Pharmaceuticals Is Top of the Class Today ↗
Eton's cure for an expensive valuation: a 99% sales growth rate. 
Via The Motley Fool
Keep an eye on the top gainers and losers in Friday's session. ↗
Via Chartmill
Friday's session: gap up and gap down stocks ↗
Via Chartmill
Eton Pharmaceuticals (NASDAQ:ETON) Soars on Q1 Beat, Raises Full-Year Guidance ↗
Via Chartmill
Eton Pharmaceuticals (NASDAQ:ETON) Posts Mixed Q4 2025 Results with Revenue Beat and EPS Miss ↗
Via Chartmill
News headline image
Earnings Scheduled For November 6, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 7, 2025 ↗
 
Via Benzinga
News headline image
A Look Ahead: Eton Pharmaceuticals's Earnings Forecast ↗
 
Via Benzinga
Discover the top movers in Friday's pre-market session. ↗
Via Chartmill
News headline image
Eton Pharmaceuticals Q2 Earnings Call Highlights ↗
Eton Pharmaceuticals (NASDAQ:ETON) reported second-quarter revenue nearly doubled from a year earlier, driven by the relaunch of HEMANGEOL and growth across its pediatric endocrinology and rare-disease... 
Via MarketBeat
Topics Earnings
News headline image
Eton Pharmaceuticals Q2 2026 Earnings Call: Complete Transcript ↗
Eton Pharmaceuticals (NASDAQ:ETON) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide... 
Via Benzinga
Topics Earnings
Stay updated with the stocks that are on the move in today's after-hours session. ↗
Via Chartmill
News headline image
Eton (ETON) Q1 2026 Earnings Call Transcript ↗
Eton (ETON) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Eton Pharmaceuticals Q1 Earnings Call Highlights ↗
Eton Pharmaceuticals (NASDAQ:ETON) raised its 2026 revenue outlook after reporting record first-quarter product sales and highlighting early progress from two recent product launches, DESMODA and... 
Via MarketBeat
Topics Earnings
News headline image
Eton Pharma (ETON) Earnings Call Transcript ↗
Eton Pharma (ETON) Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing ↗
Immunome develops antibody therapeutics for cancer and infectious diseases, reporting a market cap above $2 billion in the latest filing. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Manager Sells $5.1 Million Worth of LQDA Stock, According to Recent SEC Filing ↗
Liquidia develops inhaled and injectable therapies for pulmonary arterial hypertension, targeting unmet needs in the U.S. biopharma market. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Eton Pharma (ETON) Q3 2025 Earnings Transcript ↗
Eton Pharma (ETON) Q3 2025 Earnings Transcript 
Via The Motley Fool
News headline image
ETON PHARMACEUTICALS INC (NASDAQ:ETON) Reports Q3 2025 Revenue Beat and EPS Miss ↗
Eton Pharmaceuticals Q3 2025 results: A mixed quarter with a 7.6% revenue beat but a miss on earnings per share. 
Via Chartmill
News headline image
Eton (ETON) Q2 Revenue Jumps 108% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
FDA Approves Eton Pharma's Oral Drug For Adrenal Insufficiency In Pediatric Patients, Analyst Sees Boost In 2025 Revenue ↗
Eton Pharma's Khindivi has won FDA approval as a pediatric adrenal insufficiency treatment. It is projected to surge in sales and launch in the U.S. in June 2025. 
Via Benzinga
News headline image
A Glimpse Into The Expert Outlook On Eton Pharmaceuticals Through 4 Analysts ↗
 
Via Benzinga
News headline image
Evaluating ETON PHARMACEUTICALS INC (NASDAQ:ETON) using Mark Minervini’s winning stock formula ↗
A fundamental and technical analysis of (NASDAQ:ETON): Is ETON PHARMACEUTICALS INC (NASDAQ:ETON) suited for high growth investing? 
Via Chartmill
News headline image
Earnings Scheduled For May 13, 2025 ↗
 
Via Benzinga
News headline image
5 Analysts Assess Eton Pharmaceuticals: What You Need To Know ↗
 
Via Benzinga
News headline image
Earnings Scheduled For March 18, 2025 ↗
 
Via Benzinga
News headline image
Eton Pharma Plans FDA Filing For ET-600 Oral Desmopressin Next Month, Eyes 2026 Launch ↗
Eton Pharmaceuticals' ET-600 met bioequivalence standards in a study, with an FDA filing planned for April 2025 and a potential launch in early 2026. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Rocket Companies, Novo Nordisk And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.